Protagonist Logo. Click to navigate to a home page

UEG Week

October 15-19, 2016 12:00 PM ET

Vienna Austria United States


Poster Number: P0298

Poster Title: Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (alpha4-beta7 Integrin Antagonist) in Normal Healthy Volunteers

Date and Time: Monday October 17, 10:30 - 17:00, presentation 12:30 - 13:30 CET

Presenting Author: Richard S. Shames, MD, Protagonist Chief Medical Officer


Poster Number: P0792

Poster Title: Pharmacokinetics and Pharmacodynamics Following Oral Administration of PTG-100, a Peptide Antagonist of Integrin alpha4-beta7

Date and Time: Tuesday October 18, 9:00 to 17:00, presentation 12:30 - 13:30 CET

Presenting Author: Thamil Annamalai, M.S., Protagonist Senior Director, Preclinical Development

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.